Literature DB >> 199956

Clinical characteristics of the lethal cytomegalovirus infection following renal transplantation.

R L Simmons, A J Matas, L C Rattazzi, H H Balfour, J R Howard, J S Najarian.   

Abstract

An ongoing prospective study of the role of viruses in renal transplant recipients has provided identification of two patterns of cytomegalovirus (CMV) infection. In both patterns, fever and leukopenia occur within 6 months after transplant. In addition, the benign form is characterized by renal biopsy evidence of rejection and brisk Antibody responses to CMV. The lethal syndrome runs a typical 4 week course, beginning with prostration, orthostatic hypotension, mild hypoxemia and progressing to severe pulmonary and hepatic dysfunction, muscle wasting, central nervous system depression, and death. antibody responses to CMV are minimal, and renal biopsy does not show rejection despite elevation of serum creatinine. At autopsy, CMV is found in lung, liver, kidney, gastrointestinal tract, and brain. Successful management of the potentially lethal kidney, gastrointestinal tract, and brain. Successful management of the potentially lethal CMV syndrome requires rapid clinical recognition and immediate reduction of immunosuppressive therapy. future prospects for control include development of a CMV vaccine and specific antiviral chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 199956

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  33 in total

1.  Disseminated cytomegalovirus infection in immunodeficient rhesus monkeys.

Authors:  G B Baskin
Journal:  Am J Pathol       Date:  1987-11       Impact factor: 4.307

2.  Disseminated cytomegalovirus infection. Molecular analysis of virus and leukocyte interactions in viremia.

Authors:  R L Saltzman; M R Quirk; M C Jordan
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

3.  Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1beta triggers reactivation of latent cytomegalovirus in immunocompetent mice.

Authors:  Charles H Cook; Joanne Trgovcich; Peter D Zimmerman; Yingxue Zhang; Daniel D Sedmak
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Ganciclovir for invasive cytomegalovirus infection in renal allograft recipients.

Authors:  R Hrebinko; M L Jordan; J S Dummer; D P Hickey; R Shapiro; C Vivas; T E Starzl; R L Simmons; T R Hakala
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

5.  Adult pulmonary cytomegalic inclusion disease: report of a case.

Authors:  J D Browning; I A More; J F Boyd
Journal:  J Clin Pathol       Date:  1980-01       Impact factor: 3.411

6.  Fatal cytomegalovirus infection after renal transplantation.

Authors: 
Journal:  Br Med J       Date:  1978-06-10

Review 7.  Infections in solid-organ transplant recipients.

Authors:  R Patel; C V Paya
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

8.  Evaluation of four methods for cytomegalovirus antibody detection for use by a bone marrow transplantation service.

Authors:  D S Leland; K A Barth; E B Cunningham; J Jansen; G J Tricot; M L French
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

9.  Antiviral prevention of sepsis induced cytomegalovirus reactivation in immunocompetent mice.

Authors:  Meghan R Forster; Joanne Trgovcich; Peter Zimmerman; Alexander Chang; Cortland Miller; Paul Klenerman; Charles H Cook
Journal:  Antiviral Res       Date:  2009-12-11       Impact factor: 5.970

10.  Therapeutic use of ganciclovir for invasive cytomegalovirus infection in cadaveric renal allograft recipients.

Authors:  M L Jordan; R L Hrebinko; J S Dummer; D P Hickey; R Shapiro; C A Vivas; R L Simmons; T E Starzl; T R Hakala
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.